Montelukast Sodium Market

The Montelukast Sodium market is projected to grow at a CAGR of 5.2% from 2025 to 2035, driven by the rising global incidence of respiratory conditions such as asthma and allergic rhinitis. Montelukast Sodium is a leukotriene receptor antagonist that blocks substances responsible for inflammation, bronchoconstriction, and allergy symptoms, making it a widely prescribed long-term controller medication. Its use in both monotherapy and combination therapy, especially in pediatric care and maintenance treatment, contributes to sustained demand. The availability of various dosage forms, such as granules and chewable tablets, supports broader adoption across age groups, enhancing compliance in chronic management.

Geographically, North America leads the global market for Montelukast Sodium due to the high prevalence of asthma and allergic rhinitis, with strong healthcare infrastructure and insurance coverage driving prescriptions. Europe follows, particularly in countries like Germany, the UK, and France, where preventive respiratory care is emphasized. Asia-Pacific is the fastest-growing region, fueled by increasing urban pollution, awareness campaigns for asthma control, and the expansion of generic pharmaceutical manufacturing. Latin America and the Middle East & Africa are also showing rising usage as respiratory healthcare access improves and generic formulations become more widely distributed.

The market report is evolving with a firm position in global respiratory care due to its proven efficacy, multiple dosage formats, and broad therapeutic indications. As respiratory health gains greater attention post-pandemic, the demand for long-term controllers is expected to stay strong. Manufacturers with capabilities in pediatric-grade, taste-masked, and high-purity formulations are likely to gain a competitive advantage, especially in the high-volume generic market.